Masaru Matsuda Sells 8,338 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Masaru Matsuda sold 8,338 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $12.70, for a total transaction of $105,892.60. Following the sale, the insider now directly owns 178,692 shares of the company’s stock, valued at approximately $2,269,388.40. This trade represents a 4.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Masaru Matsuda also recently made the following trade(s):

• On Tuesday, November 19th, Masaru Matsuda sold 1,775 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $9.68, for a total transaction of $17,182.00.

Arcutis Biotherapeutics Stock Performance

Shares of Arcutis Biotherapeutics stock opened at $12.42 on Friday. The stock’s fifty day simple moving average is $13.68 and its 200 day simple moving average is $11.12. The company has a current ratio of 2.46, a quick ratio of 2.38 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $1.45 billion, a PE ratio of -6.94 and a beta of 1.29. Arcutis Biotherapeutics, Inc. has a 12 month low of $5.38 and a 12 month high of $16.20.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. The company had revenue of $44.76 million for the quarter, compared to analyst estimates of $38.05 million. On average, research analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current year.

Analyst Upgrades and Downgrades

ARQT has been the topic of a number of analyst reports. Mizuho increased their price target on Arcutis Biotherapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of Arcutis Biotherapeutics in a research note on Monday, January 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Institutional Trading of Arcutis Biotherapeutics

A number of large investors have recently bought and sold shares of ARQT. Point72 DIFC Ltd bought a new position in Arcutis Biotherapeutics in the third quarter valued at approximately $25,000. Venturi Wealth Management LLC acquired a new stake in shares of Arcutis Biotherapeutics during the fourth quarter worth $46,000. Algert Global LLC bought a new stake in Arcutis Biotherapeutics in the 2nd quarter valued at $97,000. Erste Asset Management GmbH bought a new stake in Arcutis Biotherapeutics in the 3rd quarter valued at $104,000. Finally, LVW Advisors LLC acquired a new position in Arcutis Biotherapeutics in the 4th quarter worth $166,000.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.